Literature DB >> 27784171

Physiopathological factors affecting the diagnostic value of serum HE4-test for gynecologic malignancies.

Wanglei Qu1, Jinping Li2, Ping Duan1, Zuoqing Tang3, Fengbiao Guo2,4, Haibin Chen4, Xueqiong Zhu1, Shi-Wen Jiang1,2.   

Abstract

INTRODUCTION: Serum epididymis protein 4 (HE4) represents a useful biomarker for the management of ovarian cancer and endometrial cancer patients. However, HE4 levels are affected by many physiopathological conditions or disorders that should be taken into consideration for an efficient application of this biomarker. Areas covered: The review provides an up-to-date reference on the multiple physiopathological factors that cause fluctuation of HE4 serum levels, and evaluates their impact on HE4-test in clinical settings. Potential mechanisms underlying the regulation of HE4 expression are also discussed. The review is based on data from literature search of PubMed and the author's opinions. Expert commentary: Studies have shown that physiopathological factors such as age, infection/inflammation, renal function, menopause and hormonal levels impose significant impacts on HE4 serum levels. HE4 amount shed into the circulation is related to HE4 expression and secretion by tumor as well as normal tissues, which is affected by cancer heterogeneity, vascular permeability, renal clearance and HE4 degradation. Investigation on interfering factors builds a basis for the construction of a quantitative logarithm for individualized application of HE4-test in clinical settings.

Entities:  

Keywords:  HE4; biomarker; diagnosis; gynecologic cancers; prognosis

Mesh:

Substances:

Year:  2016        PMID: 27784171     DOI: 10.1080/14737159.2016.1251317

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN: 1473-7159            Impact factor:   5.225


  8 in total

1.  Falsely elevated human epididymis protein 4 results and Risk of Ovarian Malignancy Algorithm in polymorbid women after solid organ transplantation: A pilot and case-control study.

Authors:  Janka Franeková; Josef Cindr; Petra Lavríková; Jitka Komrsková; Peter Sečník; Věra Lánská; Antonín Jabor
Journal:  J Clin Lab Anal       Date:  2018-03-24       Impact factor: 2.352

2.  The clinical significance of DJ-1 and HE4 in patients with endometrial cancer.

Authors:  Marco Benati; Martina Montagnana; Elisa Danese; Elisa Paviati; Silvia Giudici; Orazio Ruzzenente; Massimo Franchi; Giuseppe Lippi
Journal:  J Clin Lab Anal       Date:  2017-04-04       Impact factor: 2.352

3.  Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-γ, TNF-α and PD-1/PD-L1 in comparison to established serum tumor markers.

Authors:  Klara Dorman; Miriam Gerckens; Stefan Boeck; Stefan Holdenrieder; Stephan Kruger; Kimberly Krueger; Zsuzsanna Mayer; Alexander Rupp; Danmei Zhang; Lena Weiss; C Benedikt Westphalen; Michael Haas; Michael Guenther; Steffen Ormanns; Frank Klawonn; Jens Werner; Michael von Bergwelt-Baildon; Volker Heinemann
Journal:  J Cancer Res Clin Oncol       Date:  2022-06-23       Impact factor: 4.553

4.  The Association between Human Epididymis Secretory Protein 4 and Metabolic Syndrome.

Authors:  Peng-Fei Li; Yu-Jen Lin; Yao-Jen Liang; Wei-Liang Chen
Journal:  J Clin Med       Date:  2022-04-22       Impact factor: 4.964

5.  The Performance of HE4 Alone and in Combination with CA125 for the Detection of Ovarian Cancer in an Enriched Primary Care Population.

Authors:  Chloe E Barr; Garth Funston; David Jeevan; Sudha Sundar; Luke T A Mounce; Emma J Crosbie
Journal:  Cancers (Basel)       Date:  2022-04-24       Impact factor: 6.575

6.  Multi-platform Affinity Proteomics Identify Proteins Linked to Metastasis and Immune Suppression in Ovarian Cancer Plasma.

Authors:  Johannes Graumann; Florian Finkernagel; Silke Reinartz; Thomas Stief; Dörte Brödje; Harald Renz; Julia M Jansen; Uwe Wagner; Thomas Worzfeld; Elke Pogge von Strandmann; Rolf Müller
Journal:  Front Oncol       Date:  2019-11-01       Impact factor: 6.244

7.  Serum HE4 and CA125 combined to predict and monitor recurrence of type II endometrial carcinoma.

Authors:  Quan Quan; Qianqian Liao; Wanchun Yin; Shuwei Zhou; Sainan Gong; Xiaoling Mu
Journal:  Sci Rep       Date:  2021-11-04       Impact factor: 4.379

8.  Baseline Serum HE4 But Not Tissue HE4 Expression Predicts Response to the Levonorgestrel-Releasing Intrauterine System in Atypical Hyperplasia and Early Stage Endometrial Cancer.

Authors:  Roya Behrouzi; Neil A J Ryan; Chloe E Barr; Abigail E Derbyshire; Y Louise Wan; Zoe Maskell; Katie Stocking; Philip W Pemberton; James Bolton; Rhona J McVey; Emma J Crosbie
Journal:  Cancers (Basel)       Date:  2020-01-23       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.